German pharmaceutical company BioNTech is confident that its coronavirus vaccine works against the new UK variant but further studies are needed to be completely sure, its chief executive said.
The variant, detected mainly in London and the south east of England in recent weeks, has sparked concern worldwide because of signs that it may spread more easily.
While there is no indication it causes more serious illness, numerous countries in Europe and beyond have restricted travel from the UK as a result.
"We don't know at the moment if our vaccine is also able to provide protection against this new variant," chief executive Ugur Sahin told a news conference the day after the vaccine was approved for use in the European Union.
"But scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variants."
Mr Sahin said the proteins on the UK variant are 99% the same as on the prevailing strains, and therefore BioNTech has "scientific confidence" that its vaccine will be effective.
"But we will know it only if the experiment is done and we will need about two weeks from now to get the data," he said.
"The likelihood that our vaccine works ... is relatively high."
Should the vaccine need to be adjusted for the new variant, the company could do so in about six weeks, Mr Sahin said, though regulators might have to approve the changes before the shots can be used.
Having to adjust the vaccine would be a blow for the rollout of immunisation campaigns in the bid to rein in the pandemic that has so far killed more than 1.7 million people worldwide.
BioNTech's vaccine, which was developed together with US pharmaceutical company Pfizer, has been authorised for use in more than 45 countries including Britain, the United States and the EU.
Hundreds of thousands of people have already received the shots.
The companies submitted data to regulators showing the vaccine, which goes by the brand name COMIRNATY in Europe, is 95% effective in preventing infection with Covid-19.
"All countries across the EU that have requested doses will receive them in the next five days, the very initial supply, and that will be followed up next week with further supplies," said Sean Marett, BioNTech's chief commercial officer.
Several EU countries have said they plan to start vaccinating on Sunday.
Germany's health minister Jens Spahn said he expects the country to receive more than 1.3 million doses by the end of this year.
Germany is among the European countries that have banned flights from the UK because of the new variant there.
"We want to avoid for as long as we can that a possibly dangerous virus variant spreads to continental Europe," said Mr Spahn.
But Lothar Wieler, the head of Germany's national disease control centre, said it was very likely the UK variant is already circulating in Germany.
Mr Wieler, who heads the Robert Koch Institute, said it was common for viruses' genetic material to change, and that can affect how transmissible they are.
"Whether that is really the case with the variant in England is not yet entirely clear," he said.
"What is clear is that the more widely viruses spread, the more opportunity they have to change."
A leading German virologist who was initially sceptical about reports that the strain was much more contagious voiced concern after seeing further data.
Christian Drosten, a professor of virology at Berlin's Charite hospital, tweeted that "unfortunately it doesn't look good".
But Prof Drosten added: "What is positive is that cases with the mutation so far only increased in areas where the overall incidence was high or rising. So contact reduction also works against the spread of the mutation."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here